Pfizer Inc. just made headlines by acquiring a promising biotech firm. The strategic move aims to enhance Pfizer's portfolio ...

Parnassus Investments, an investment management firm that focuses on owning a concentrated portfolio of U.S. large cap stocks ...

Global pharmaceutical company Pfizer (NYSE:PFE) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with ...

Pfizer (PFE) recently announced positive topline results from the Phase 3 EV-303 clinical trial, showcasing promising ...

With the end of the pandemic, sales of Pfizer’s PFE COVID products, Comirnaty and Paxlovid, have declined from their peak.

Pfizer stock is incredibly cheap following management's raise of its 2025 adjusted earnings per share guidance. It's at just ...

Pfizer Inc. has just upgraded its 2025 earnings forecast, fueling a bullish sentiment among analysts. After its Q2 earnings ...

Exelixis(EXEL) is developing zanzalintinib— a next-generation oral investigational tyrosine kinase inhibitor (TKI) — which inhibits the activity of receptor tyrosine kinases implicated in cancer ...

Pfizer's COVID-19 vaccine for children under five may lose FDA authorization, leading to potential supply shortages. Modern ...

According to a Bloomberg report, Pfizer has requested that the approval stay in place through the coming fall season.

Pfizer, Inc. PFE reported fourth-quarter 2021 adjusted earnings per share of $1.08, which comprehensively beat the Zacks Consensus Estimate of 85 cents per share. Earnings rose 152% year over year.

This 41% rise for PFE stock since late 2020 was driven by: 1. Pfizer’s revenue, which grew a solid 122% to $92.4 billion over the last twelve months, compared to just $41.7 billion in 2020. This ...